PORTEFEUILLE

IMAI MedTech is an ETH spin-off and marks a significant leap forward in tissue diagnostics, introducing an automated 3D histology platform that integrates robotics, electrical engineering and advanced imaging. The name cleverly combines 'IM' for imaging, 'AI' for artificial intelligence and coincides with the Japanese word ‘ima’, meaning 'now', emphasizing its innovative approach. This technology aims to overcome the limitations of traditional 2D histology by enabling detailed, three-dimensional examinations of tissues, thus improving diagnostic accuracy and enabling early cancer diagnosis in the future.
Using artificial intelligence and robotics, IMAI not only promises to improve the accuracy of cancer diagnoses, but also to accelerate the diagnostic process, potentially leading to better patient outcomes through timely and targeted treatments. In addition, its advanced 3D imaging capabilities offer new insights into disease mechanisms, contributing to medical research and the development of new therapies.
Scheduled to be integrated into the clinical setting after rigorous validation phases, IMAI represents a transformative advancement in medical diagnostics, aiming to improve both patient care and research outcomes through its cutting-edge technology.

At the project's inception, steps include finalizing the automated 3D histology prototype for research, implementing a regulatory-compliant QMS, and developing image analysis software for clinical use. Interim goals involve prototype validation, customer acquisition, and pilot study completion. This project fills the gap in accurate cancer diagnostics, with ongoing implementation activities such as software development and regulatory preparations. With industry partnerships, IMAI aims at enhancing product reach and application. Specifically, collaborations with Swiss university hospitals, a leading microscopy company, and data science and imaging groups/companies are pivotal in advancing our prototype development and clinical design. The project is set to continue with advancements in clinical design, backed by significant follow-up funding to ensure sustainable development and market penetration, leveraging these strategic partnerships to navigate the complexities of healthcare innovation.